An experimental drug developed at Michigan Medicine has reversed a severe form of fatty liver disease in animal studies by protecting the gut lining and reducing harmful bacteria that trigger liver inflammation, researchers report. The compound, DT-109, targets the gut rather than the liver directly, offering a potential new approach to treating metabolic dysfunction-associated steatohepatitis (MASH), a condition affecting roughly 7% of the global population.
Scientists at the University of Michigan have shown that the experimental compound DT-109 can reverse MASH in animal models by interrupting a chain reaction that begins in the gut. The findings, published in The Journal of Clinical Investigation, reveal how changes in gut bacteria contribute to liver damage and how the drug disrupts that process.
The research team, led by Eugene Chen, M.D., Ph.D., Frederick G. L. Huetwell Professor of Cardiovascular Medicine at the University of Michigan Medical School, had previously demonstrated that DT-109 could improve MASH in animals. The new study explains the mechanism: DT-109 reduces excessive growth of the bacterium Clostridium perfringens in the intestines. This bacterium produces ammonia, which can damage the gut's protective epithelial barrier. When the barrier weakens, toxins and other microbial products escape into the bloodstream and travel to the liver, where they provoke inflammation and activate immune cells, including CD8+ T cells, worsening liver damage.
"We see clear evidence that DT-109 protects the gut epithelial barrier, reducing the systemic influx of harmful microbial products that are thought to contribute to MASH development and progression," Chen said in a statement. "This compound shows benefits to the gastrointestinal system and has great potential as a treatment for MASH."
MASH is a severe form of fatty liver disease characterised by fat accumulation, inflammation and cellular damage. It can progress to cirrhosis, liver cancer and liver failure. While treatment options have improved, effective therapies remain limited. DT-109 is a glycine-based tripeptide, a small molecule made from three amino acids.
The study confirms that a disease centered in the liver can be strongly influenced by events occurring in the gut, supporting further investigation of gut-targeted treatments for MASH.
Analysis
Why This Matters
- MASH affects approximately 7% of the world's population and can lead to cirrhosis, liver cancer and liver failure, yet effective treatments remain limited.
- The drug targets the gut rather than the liver, opening a new therapeutic avenue that could complement existing approaches.
- If confirmed in human trials, DT-109 could offer a treatment option for millions of patients worldwide who currently have few alternatives.
Background
MASH (metabolic dysfunction-associated steatohepatitis) is a serious, progressive form of non-alcoholic fatty liver disease. It involves fat accumulation in the liver accompanied by inflammation and liver cell damage, often linked to obesity, type 2 diabetes and metabolic syndrome. The condition can silently progress over years, with many patients unaware until significant liver scarring has occurred. Current treatments include lifestyle changes and recently approved drugs, but they are not effective for all patients and can have side effects.
Key Perspectives
Researchers (University of Michigan): The drug DT-109 works by reducing harmful gut bacteria, protecting the intestinal lining and preventing inflammatory substances from reaching the liver. They see clear evidence of benefit in animal models and believe the compound has great potential as a MASH treatment.
Skeptics and clinicians: The results are confined to animal studies. Human physiology, especially the gut microbiome and immune system, differs significantly. The drug's safety, efficacy and optimal dosing in humans remain unproven. Translation from animal models to clinical practice in MASH has historically been challenging.
Patients and advocacy groups: A new gut-targeted approach could be promising, particularly for patients who do not respond to existing therapies. However, they will be watching for early-phase human trial results, which are likely years away.
What to Watch
- Initiation of Phase 1 clinical trials in humans to assess safety and tolerability.
- Further preclinical studies in other animal models to confirm the mechanism and rule out off-target effects.
- Regulatory interest: whether the U.S. Food and Drug Administration grants fast-track or breakthrough therapy designation if early data are promising.